Hepion Pharmaceuticals (NASDAQ:HEPA) Shares Up 1.3% – Here’s Why

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) shares rose 1.3% during mid-day trading on Monday . The stock traded as high as $0.18 and last traded at $0.17. Approximately 17,007,225 shares changed hands during mid-day trading, a decline of 59% from the average daily volume of 41,071,859 shares. The stock had previously closed at $0.17.

Hepion Pharmaceuticals Stock Up 1.3 %

The company has a market cap of $1.19 million, a price-to-earnings ratio of -0.04 and a beta of 1.65. The stock’s 50-day simple moving average is $0.44 and its 200 day simple moving average is $0.60.

Hedge Funds Weigh In On Hepion Pharmaceuticals

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP acquired a new stake in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned approximately 3.33% of Hepion Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 17.24% of the company’s stock.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.